Synthetic applications of boryl carboxylates

2019年春，我们发现了一类新的具有尚未开发的合成潜力的分子--羧酸硼酯(CBA)。我们随后申请了一项专利，以保护这种物质的组成。CBA技术很快引起了默克公司的注意，我们发起了一项合作，以了解这种新化学物质的潜在应用范围。因此，我们最近在Angewandte Chemie与默克公司联合发表了一篇论文。我们还从NSERC获得了市场评估资金，使我们能够保留Adventus Research的服务。Adventus的G.Svoboda博士进行了一项彻底的市场评估研究。本I2I应用程序考虑了该报告中的主要信息，并将重点放在将进一步降低我们的技术风险的应用程序上，因为它已经足够成熟。在这份报告的帮助下，我们现在有了加强CBA技术商业价值的具体步骤。其中包括一系列CBA衍生物的开发，以及这些分子在合成具有挑战性的杂环中的优异性能的展示。我们的合作伙伴(默克、Eurofins Alphora和MillipreSigma)非常适合帮助我们扩大专利申请范围，并将这项技术推向更接近许可的位置。

In the Spring of 2019, we discovered boryl carboxylates (CBA), a new class of molecules with untapped synthetic potential. We subsequently applied for a patent to protect this composition of matter. The CBA technology quickly attracted the attention of Merck and we initiated a collaboration in order to understand the scope of potential applications of this new chemistry. As a result, we recently published a joint paper with Merck in Angewandte Chemie. We also received market assessment funding from NSERC, allowing us to retain the services of Adventus Research. Dr. G. Svoboda of Adventus has carried out a thorough market assessment study. The present I2I application considers the main messages from that report and focuses on the applications that will further de-risk our technology now that it is sufficiently mature. With the help of this report, we now have specific steps to strengthen the commercial value of the CBA technology. These include the development of a range of CBA derivatives as well as the demonstration of superior properties of these molecules in the synthesis of challenging heterocycles. Our partners (Merck, Eurofins Alphora, and MilliporeSigma) are ideally suited to help us broaden patent claims and position this technology closer to licensing.